Is Akeso (SEHK:9926) Undervalued On Its Phase III Colon Cancer Trial News?

Simply Wall St.10-19

Akeso (SEHK:9926) has put fresh attention on its core oncology program after dosing the first patient in a Phase III trial of cadonilimab for perioperative MSI-H or dMMR colon cancer. Akeso’s latest ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2676549689?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-19 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676549689","market":"hk","top_or_hot":-1,"title":"Is Akeso (SEHK:9926) Undervalued On Its Phase III Colon Cancer Trial News?","media":"Simply Wall St.","content":"<div>\n<p>Akeso (SEHK:9926) has put fresh attention on its core oncology program after dosing the first patient in a Phase III trial of cadonilimab for perioperative MSI-H or dMMR colon cancer. Akeso’s latest ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-akeso-sehk9926-undervalued-on-its-phase-iii-colon-cancer\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Akeso (SEHK:9926) Undervalued On Its Phase III Colon Cancer Trial News?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Akeso (SEHK:9926) Undervalued On Its Phase III Colon Cancer Trial News?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-19 17:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-akeso-sehk9926-undervalued-on-its-phase-iii-colon-cancer><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Akeso (SEHK:9926) has put fresh attention on its core oncology program after dosing the first patient in a Phase III trial of cadonilimab for perioperative MSI-H or dMMR colon cancer. Akeso’s latest ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-akeso-sehk9926-undervalued-on-its-phase-iii-colon-cancer\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348767384.USD","symbol_name":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-akeso-sehk9926-undervalued-on-its-phase-iii-colon-cancer","article_id":"2676549689","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-akeso-sehk9926-undervalued-on-its-phase-iii-colon-cancer","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2676549689","pubTimestamp":1792402456,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Akeso (SEHK:9926) has put fresh attention on its core oncology program after dosing the first patient in a Phase III trial of cadonilimab for perioperative MSI-H or dMMR colon cancer.\nAkeso’s latest oncology milestone lands after a volatile stretch for the shares, with a 7 day share price return down 16.32% and a year to date share price return down 19.42% from the current HK$91.3 level. Even though the 3 year total shareholder return is up 141.85%, which keeps long term momentum intact, this...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","09926":"康方生物","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","BK1161":"生物科技","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1574":"生物医药B类股","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC"},"translate_title":"Akeso (SEHK:9926) 的 III 期结肠癌试验消息是否被低估？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":0.9,"KURE":0.6},"content_text":"Akeso (SEHK:9926) has put fresh attention on its core oncology program after dosing the first patient in a Phase III trial of cadonilimab for perioperative MSI-H or dMMR colon cancer. Akeso’s latest oncology milestone lands after a volatile stretch for the shares, with a 7 day share price return down 16.32% and a year to date share price return down 19.42% from the current HK$91.3 level. Even though the 3 year total shareholder return is up 141.85%, which keeps long term momentum intact, this comes despite a 1 year total shareholder return that has declined 25.53% and recent follow on equity offering news adding short term pressure. Spot 126 healthcare AI stocks that, like Akeso, are trying to turn high-impact clinical programs into the next wave of oncology and immunology breakthroughs.\nSo is the recent drop in Akeso mainly a verdict on dilution and risk appetite, or a temporary swing in sentiment around a business still leaning hard into high cost, high potential oncology assets? The valuation work starts there. AdvertisementMost Popular Narrative: 41% Undervalued Against the last close at HK$91.3, the most followed narrative pegs Akeso’s fair value much higher at about HK$154, which puts the recent drawdown in a very different light and turns the Phase III pipeline into the central swing factor.  The company's R&D pipeline, including advanced bispecific antibodies and ADC candidates, provides a foundation for long-term growth. This is described as setting the stage for potential increases in net margins as products move from development to commercialization. Akeso's comprehensive sales force and manufacturing capabilities, alongside anticipated growth in hospital coverage from 1,000 to 2,000, are cited as supporting a scalable commercial operation that may improve operational efficiencies and contribute to enhanced net margins.  See why 3 investors see Akeso as 41% undervalued. Result: Fair Value of HK$154 (UNDERVALUED) Still, the fair value story depends on Akeso turning a loss of CN¥967.2 million into sustainable profits while managing its heavy reliance on cadonilimab and ivonescimab. Find out about the key risks to this Akeso narrative. Another View: What Akeso’s Sales Multiple Is Saying That HK$154 fair value narrative leans on future cash flows, yet Akeso currently trades on a P/S of 20.8x while the Hong Kong biotech group sits around 8.8x and the fair ratio is 12.8x. The gap points to richer expectations on revenue today. Which story do you trust more? For a closer look at how those sales multiples stack up against what the fair ratio suggests the market could move towards, See what the numbers say about this price — find out in our valuation breakdown. SEHK:9926 P/S Ratio as at Oct 2026Next Steps Sentiment around Akeso is clearly split, which is exactly why fresh data matters more than headlines. Act quickly and review both the bear points and the 2 key rewards. Looking for more investment ideas beyond Akeso? If Akeso has you thinking harder about risk, reward, and timing, then it is worth lining up a few more targets that could sharpen your watchlist.  Target resilient compounding potential by scanning a 192 high quality undervalued stocks that blends quality fundamentals with prices that may not fully reflect underlying business strength. Lock in income-focused opportunities by reviewing a 218 dividend fortresses that screens for higher yielding payers with the balance sheets to support ongoing distributions. Lean into durability and stability by checking a 231 resilient stocks with low risk scores built to surface businesses with lower risk scores before the crowd pays attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2676549689","isCrawlerRequest":true}